sp move, page-11

Gday Kippax

I agree

The EMS management team are doing what a prudent management team should be doing, and that is progressing the product as if they were going to sell it themselves.

I know you arent suggesting this, but it would be foolish for the company to just sit on their hands and do nothing while waiting for the trial results to be collated and then waiting to sell/license the product.

The best thing they can do is advance the commercialisation pathway as much as they can, which means that any potential purchaser has to do less.

This will ultimately mean a higher sale price for the product.

In addition, in the IMO unlikely event that the company doesnt receive a suitable offer, then at least it hasnt wasted valuable time trying to source a buyer whilst doing nothing to progress the product towards commercialisation.

So yes, the company is following a proper and prudent strategy IMO, which will ultimately lead to a sale of the Artimist rights.
And there is no doubt that any meaningful goverment or NGO support would be very helpful in their cause.